SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending due to mixed reactions following its earnings release and subsequent stock movement, with community members debating whether the stock is overvalued. A significant point of discussion is Michael Burry's reported short position against the company. Despite positive earnings news, the stock's high valuation and potential AI bubble concerns are driving bearish sentiment.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI CRYPTO is gaining attention, particularly within communities focused on the Solana ecosystem, with some users expressing bullish sentiment while others discuss challenges. The community emphasizes a shared vision and encourages building together, fostering a sense of unity despite market conditions.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending amid discussions about a confirmatory trial and its potential impact on existing PMO therapies, which are facing scrutiny, while Elevidys sales remain a key focus. The community is weighing the implications for future revenue and potential FDA actions, with some speculating about a possible Roche buyout amid the uncertainty. Discussions also involve management's handling of recent data releases and their overall strategy.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending as investors assess the implications of Q3 earnings, which included a massive EPS beat, even as some profit forecasts fell slightly short. The community is actively discussing the company's growth in bookings and trips, particularly the impact of Uber One memberships, while also debating whether the stock is currently undervalued given its market dominance and future potential in autonomous vehicles. Short-term manipulation and broader market conditions are also being considered as factors influencing the stock's price movement.

Bitcoin is the first successful internet money based on peer-to-peer technology; whereby no central bank or authority is involved in the transaction and production of the Bitcoin currency. It was created by an anonymous individual/group under the name, Satoshi Nakamoto. The source code is available publicly as an open source project, anybody can look at it and be part of the developmental process.  Bitcoin is changing the way we see money as we speak. The idea was to produce a means of exchange, independent of any central authority, that could be transferred electronically in a secure, verifiable and immutable way. It is a decentralized peer-to-peer internet currency making mobile payment easy, very low transaction fees, protects your identity, and it works anywhere all the time with no central authority and banks.  Bitcoin is designed to have only 21 million BTC ever created, thus making it a deflationary currency. Bitcoin uses the SHA-256 hashing algorithm with an average transaction confirmation time of 10 minutes. Miners today are mining Bitcoin using ASIC chip dedicated to only mining Bitcoin, and the hash rate has shot up to peta hashes.  Being the first successful online cryptography currency, Bitcoin has inspired other alternative currencies such as Litecoin, Peercoin, Primecoin, and so on.  The cryptocurrency then took off with the innovation of the turing-complete smart contract by Ethereum which led to the development of other amazing projects such as EOS, Tron, and even crypto-collectibles such as CryptoKitties.

Bitcoin

Bitcoin's recent price volatility has the community debating whether a longer-term correction is underway. Some traders believe institutions are strategically selling off, while others see the dip as a bear trap before a potential rally toward previous highs. Discussions also involve the influence of broader market factors, such as the Nasdaq and potential government actions, on Bitcoin's price.

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending amid discussions about its potential as a leading privacy coin and a hedge against Bitcoin's volatility, as some community members suggest it could reach new all-time highs. The conversations also highlight its upcoming anniversary, possibly leading to increased attention and speculation about future developments. Simultaneously, some traders are noting its overbought conditions and anticipating a potential pullback.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JASMY is trending amidst mixed sentiment, with some traders citing potential partnerships and real-world utility while others express concerns about its price action and long-term viability. Community discussions revolve around identifying key resistance levels and whether the current market cap is justified. Speculation about future developments and potential catalysts continues to fuel the conversation.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending as community members assess the implications of recent earnings, raised guidance, and a notable dividend yield. Discussions include whether the market is undervaluing the stock, and speculation on potential acquisitions in the competitive obesity therapeutics market with some suggesting it may be a good long-term hold. Additionally, Michael Burry's position in PFE calls is generating buzz among investors.

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

Verastem ($VSTM) is trending as optimism grows around potential FDA approvals and encouraging clinical trial data, particularly in KRAS-mutant cancers. The community is actively discussing long-term prospects, potential buyouts, and comparisons to competitors in the oncology space. Bullish sentiment is fueled by expectations of significant valuation increases and potential for a short squeeze.

Shopify, Inc. is a global commerce company that provides essential internet infrastructure for commerce, offering trusted tools to start, scale, market, and run a retail business of any size. The Company's software enables merchants to run their business across all of their sales channels, including web and mobile storefronts, physical retail locations, social media storefronts and marketplaces. The Shopify platform provides merchants with a single view of their business across all of their sales channels and enables them to manage products and inventory, process orders and payments, fulfill and ship orders, build customer relationships, source products, leverage analytics and reporting and access financing, all from one integrated back office. The company was founded on September 28, 2004 and is headquartered in Ottawa, Canada.

Shopify Inc - Ordinary Shares - Class A (Sub Voting)

Shopify Inc

Shopify is trending as investors discuss the company's recent earnings report, which revealed revenue growth and cash flow positivity. Community members are debating whether the current valuation is justified amidst competition and broader market conditions. Some are optimistic about the company's future prospects, citing potential AI modeling and strategic partnerships with established brands.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in Boston

Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in Boston Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in Boston PR Newswire NEW YORK, Oct. 16, 2025 NEW YORK, Oct. 16, 2025...

Retail chatter around Klotho Neurosciences picked up late Thursday after the company said that the FDA had granted Orphan Drug Designation to its ALS gene therapy candidate, KLTO-202.The designation is reserved for treatments targeting rare diseases and comes with several incentives to support development.&nbsp;These include seven years of market exclusivity, tax credits for clinical trials, and a waiver of the generic drug user fee amendments (GDUFA) user fee, independent of existing intellectual property rights.At the close on Thursday, shares of&nbsp;<a href="https://stocktwits.com/symbol/KLTO">Klotho Neurosciences</a> rose 6.6% to $1.46, before slipping 6.9% to $1.36 in after-hours trading.Last month, the company reported efforts to move forward with manufacturing and process development in preparation for clinical trials of KLTO-202.&nbsp;Klotho holds rights to a unique RNA splice variant of the human alpha‑Klotho gene, licensed from the Autonomous University of Barcelona.&nbsp;This variant produces the secreted form of Klotho protein (s‑KL), known for its neuroprotective properties in the brain and spinal cord.Animal studies conducted in mouse and non-human primate models of accelerated aging, Alzheimer's disease, and ALS have demonstrated that boosting s‑KL through gene therapy yields therapeutic benefits across all tested models, according to peer-reviewed journals.&nbsp;These findings support KLTO-202’s progression into clinical development.The company expects that process development and manufacturing will take about eight months, followed by four to six months of FDA meetings, mandated animal safety studies, an investigational new drug (IND) filing, and site preparations.&nbsp;A single-dose Phase I/II trial in ALS patients is planned for the third quarter of next year.&nbsp;In a statement, CEO Joseph Sinkule said that the therapy’s goal is to deliver therapeutic s‑KL concentrations to blood, brain, and muscle tissue.KLTO-202, which uses a muscle-specific desmin promoter to drive s‑KL expression at the neuromuscular junction, remains unapproved for human use.On Stocktwits, retail sentiment for Kloto was ‘bullish’ amid ‘high’ message volume.Kloto’s stock has more than doubled in value so far in 2025.See also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/china-s-byd-chery-accused-of-subsidy-misuse-as-ev-audit-flags-121-m-in-claims/ch8c5XCR5mQ">China’s BYD, Chery Accused Of Subsidy Misuse As EV Audit Flags $121M In Claims</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Kloto Neurosciences (KLTO) said that the FDA had granted Orphan Drug Designation to its ALS gene therapy candidate, KLTO-202. (Photo credit: Getty Images)

Klotho Neurosciences Stock Jumps As FDA Grants Orphan Drug Tag To ALS Gene Therapy

The FDA’s Orphan Drug Designation offers incentives like seven years of U.S. market exclusivity, tax credits for clinical trials, and a waiver of the user fee for its ALS gene therapy.

Equity

Klotho Neurosciences (KLTO) shares exploded over 780% on Monday, their biggest single-day gain on record, after the company announced breakthrough preclinical results tied to its anti-aging gene therapy.The Omaha, Nebraska-based biotech said boosting levels of a naturally occurring protein called s-KL (secreted Klotho) extended lifespan in mice by 20% and reduced signs of aging across multiple organ systems.&nbsp;The gene therapy, delivered via the AAV9 vector, showed positive effects in both standard and accelerated aging models."The results disclosed in the paper show the potential of elevating s-KL protein expression, resulting in the reduction of age-associated degeneration in multiple organs, increasing both life and health span," said CEO Joseph Sinkule.&nbsp;Klotho owns exclusive global rights to the patented therapy, based on pioneering work from researchers at Universitat Autònoma de Barcelona. The company said its patent coverage spans the U.S., Europe, and China.Earlier studies had shown that mice with increased Klotho expression could live up to 40% longer.Retail Traders Go WildThe update triggered a retail frenzy on Stocktwits as 24-hour message volume about KLTO jumped by 250,400% — the biggest surge in the healthcare sector — while the follower count spiked by over 134%.Sentiment score peaked at ‘extremely bullish’ levels (100/100) by the end of Monday.<figure class="image"><img style="aspect-ratio:1318/914;" src="https://news.stocktwits-cdn.com/KLTO_sentiment_and_message_volume_as_of_Jun_9_png_d3adf0d02d.webp" alt="KLTO sentiment and message volume as of Jun 9.png" width="1318" height="914"><figcaption>KLTO sentiment and message volume as of Jun 9. | source: Stocktwits</figcaption></figure>One user predicted the stock would surge nearly fivefold to $5.<stembedurl>https://stocktwits.com/Kcricket33/message/617354438</stembedurl>"Pretty wild news, obviously digested well today… will watch for continuation tomorrow using the pivot of today's highs in confluence with trend support as entry criteria. Range to $2.8, $3+," said another.<stembedurl>https://stocktwits.com/KevMomentum/message/617353716</stembedurl>Klotho is targeting neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS, leveraging s-KL in both DNA/RNA therapies and genomics-based diagnostics.<a href="https://stocktwits.com/symbol/KLTO">KLTO stock</a> is now up over 271% YTD, returning to levels last seen in July 2024.&nbsp;However, short interest has also climbed, rising from 1.1% in January to 7.1% last week, per Koyfin data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Klotho Neurosciences Stock Skyrockets On Anti-Aging Gene Therapy Breakthrough: Retail Traders Over The Moon

The gene therapy, delivered via the AAV9 vector, showed positive effects in both standard and accelerated aging models.

Klotho Neurosciences, Inc. engages in the provision of new therapies to treat neurodegenerative diseases. It offers cell and gene therapy. The company was founded by Joseph Sinkule on August 2, 2004 and is headquartered in Omaha, NE.

Klotho Neurosciences Inc.

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Robinhood Markets Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$0.513
Prev Close	$0.5301
Open	$0.5408
Dividend Yield	0.00%
50-Day Moving Average	$0.5666
Beta	0.94
Avg. Volume	1.72M
PE Ratio	-1.13

52-Week High	$3.91
52-Week Low	$0.1135
Market Capitalization	$36.08M
EPS (Annual)	-$0.3195
Price to Book	2.54
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

KLTO
Klotho Neurosciences Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest KLTO News

KLTOKlotho Neurosciences Inc.